EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer
Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.
Related Articles
Building Upon an “Era of Therapeutic Refinement” in Pancreatic Cancer
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
CNSide Can Aid Diagnosis, Management of Leptomeningeal Metastases
CNSide can aid the diagnosis and management of leptomeningeal metastases in patients with cancer, a new study suggests.
Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements
Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.
Aneuploid Cells in Normal Breast Tissue Challenge Cancer Paradigms
Normal breast tissue harbors rare populations of aneuploid cells, displaying genetic changes often associated with invasive breast cancer—a finding that challenges the reliability of genomic…
Tumor heterogeneity and cooperating cancer hallmarks driven by divergent EMT programs
Abstract. Epithelial-to-mesenchymal transition (EMT) is known to play roles in orchestrating cellular plasticity across many physiological and pathological contexts. Partial EMT, wherein cells maintain both…
As Trump’s second term nears, Republican support for NIH is at a low point By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research – The Cancer Letter
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier…
ASH in a Flash – Artificial Intelligence in Hematology: From Generative AI to Ethics & Applications
#ASHinaFlash, your fast track to essential #ASH24 content! Get expert highlights of must-see sessions and quick takes on the latest #hematology breakthroughs…
FDA Grants Fast Track Designation to LBS-007 in AML
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia
This was a phase 2 trial of all-trans retinoic acid plus arsenic trioxide with or without gemtuzumab ozogamicin in acute promyelocytic leukemia, in which patients…
Nominations
NOMINATE The Giants of Cancer Care ® program, presented by OncLive ®, recognizes and celebrates the individuals who have achieved landmark successes within the global…